一品红子公司获甲硫酸新斯的明注射液注册证书

Core Viewpoint - The company has received approval for its new drug, Methylthio-2-aminobutane injection, which is indicated for various medical conditions, enhancing its product portfolio and potential market reach [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the drug registration certificate from the National Medical Products Administration for Methylthio-2-aminobutane injection [1] - The approved drug is an anticholinesterase agent, used to counteract the residual muscle relaxation effects of non-depolarizing muscle relaxants at the end of surgery [1] Group 2: Product Indications - The indications for Methylthio-2-aminobutane injection include treatment for myasthenia gravis, postoperative functional intestinal distension, and urinary retention [1]